Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant

Leuk Lymphoma. 2016;57(3):714-6. doi: 10.3109/10428194.2015.1061190. Epub 2016 Jan 11.

Authors

Colombe Saillard¹, Jean El Cheikh¹, Angela Granata¹, Diane Coso¹, Jean-Marc Schiano¹, Reda Bouabdallah¹, Didier Blaise^{1

2}, Nathalie Charrier³, Florence Broussais¹

Affiliations

¹ a Hematology Department , Institut Paoli Calmettes , Marseille , France ;
² b Aix Marseille University , Marseille , France ;
³ c Nuclear Medicine , Institut Paoli Calmettes , Marseille , France.

PMID: 26750740
DOI: 10.3109/10428194.2015.1061190

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzofurans / therapeutic use*
Female
Fluorodeoxyglucose F18
Hematopoietic Stem Cell Transplantation*
Histone Deacetylase Inhibitors / therapeutic use*
Humans
Hydroxamic Acids / therapeutic use*
Lymphoma, T-Cell, Peripheral / diagnosis
Lymphoma, T-Cell, Peripheral / therapy*
Positron Emission Tomography Computed Tomography
Recurrence
Transplantation Conditioning*
Transplantation, Homologous
Treatment Outcome

Substances

Benzofurans
Histone Deacetylase Inhibitors
Hydroxamic Acids
Fluorodeoxyglucose F18
abexinostat